Location: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=clinicalinvestigatorsdisqualificationproceedings
Compliance and Enforcement
Regulatory Activities
Clinical Investigators - Disqualification Proceedings
Return to Introductory Page
Name Center Status Date of status Date NIDPOE Issued Date NOOH Issued Link to NIDPOE Letter Link to NOOH Letter Davidson, Jeffrey N., DVM
CVM
Disqualified
07/20/2009
11/07/1997
Day, Phillip L., MD
CDER
Disqualified
08/28/1975
DeAbate, Carl Andrew, MD
CDER
Disqualified
02/05/2004
04/13/2001
11/28/2003
PDF Text
PDF Text Diamond, Bruce I., PhD
CDER
Disqualified
02/10/1999
Doss, Jr., William L., MD
CDER
Disqualified
06/14/1979
11/15/1977
03/03/1978
Dressler, David M., MD
CDER
Disqualified
03/14/1984
02/07/1984
Dunlop, Edwin, MD
CDER
Reinstated
12/24/1970
Edwards, Thomas B., MD
CDER
Restricted
01/26/1998
Ericsson, Arthur Dale, MD
CDER
Disqualified
05/04/2009
03/31/2008
03/04/2009
PDF Text
PDF Text Fabre, Louis F., MD, PhD
CDER
Restricted
06/23/2008
01/19/2005
PDF Text
Farber, Harold F., MD
CDER
Disqualified
07/18/2005
Faxon, David P., MD
CDER
Restrictions Removed
06/19/2005
04/07/2000
Text
Feurst, Samuel I., MD
CDER
Disqualified
10/02/1984
09/23/1983
Fiddes, Robert A., MD
CDER
Disqualified
06/01/1999
09/12/1997
04/07/1998
PDF Finnerty, Jr., Frank A., MD
CDER
Restrictions Removed
12/04/1988
12/04/1985
Fogari, Robert, MD
CDER
Totally Restricted
04/24/1985
Fox, Jr., Robert A., MD
CDER
Disqualified
02/15/1989
Franklin, William C., MD
CDER
Disqualified
11/09/1982
10/20/1981
08/26/1982
Froning, Edward C., MD
CDER
Disqualified
04/10/1976
07/31/1975
Fuller, Ronald R., DVM
CVM
Disqualified
01/29/1988
03/11/1986
08/04/1986
Gaman, Walter N., MD
CDER
Restrictions Removed
07/31/2006
10/23/2002
PDF Text
Gamarra, Miguel H., MD
CDER
Disqualified
05/31/1983
Garcia, Julio M., MD
CDER
Restricted
10/19/1995
Garetz, Floyd K., MD
CDER
Disqualified
11/23/1982
Garfinkel, Barry D., MD
CDER
Totally Restricted
05/14/1994
Garjian, Peggy Ann, MD
CDER
Disqualified
09/22/2008
08/25/2008
PDF Text
Gatenby, Robert A., MD
CDER
Reinstated pursuant to Agreement
02/16/2023
09/25/1988
Gelfand, Michael C., MD
Burea
Not Disqualified
09/11/1981
Gentry, Layne O., MD
CDER
Disqualified
06/18/2008
03/23/1998
04/15/1999
PDF
PDF Text Gillespie, Larrian, MD
CDER
Disqualified
02/02/1989
05/20/1988
Gooding, John M., DO
CDER
Totally Restricted
11/07/1986
06/19/1984
Grecu, Eugene O., MD, PhD
CDER
Disqualified
03/25/1999
05/15/1992
10/14/1994
Guerin, Bernard K., MD
CDER
Disqualified
11/13/1984
07/02/1984
Gupta, Suresh, MD
CDER
Not Disqualified
06/29/2009
09/12/2008
PDF Text
Guy, Matthew J., MD
CDER
Disqualified
07/25/2008
01/24/2008
PDF Text
Hagaman, Martha H., MD
CDER
Restricted
01/09/2006
03/01/2005
PDF Text
Halikas, James A., MD
CDER
Disqualified
01/17/2001
11/04/1996
04/02/1997
PDF Hendrick, Kim C., MD
CDER
Disqualified
12/11/2009
05/11/2006
07/01/2009
PDF Text
Hofmann, Alan F., MD
CDER
Restricted
11/21/1995
Holland, James A., MD
CDER
Disqualified
08/25/2008
09/22/2004
08/14/2007
PDF Text
Holmes, Amy S., MD
CDER
Disqualified
01/11/2011
12/02/2010
PDF Text
Hopkinson, III., John H., MD
CDER
Not Disqualified – Adequate Assurances 1
06/03/1983
Hotchkiss, Jr., Dwight J., MD
CDER
Disqualified
06/25/1984
John, Jr., J T., MD
CDER
Disqualified
11/04/1983
Jolly, Jr., Henry W., MD
CDER
Restrictions Removed
11/17/1986
11/17/1983
Kapner, Jamie, MD
CDER
Disqualified
09/10/2007
08/15/2007
PDF Text
Katz, Lois Anne, MD
CDER
Restrictions Removed
08/21/2005
08/21/2000
PDF
Khooblall, Khem L., MD
CDER
Disqualified
06/17/1998
Kim, Christopher M., MD
CBER
Not Disqualified
10/20/1993
03/23/1993
Kirkman Campbell, Maria Anne, MD
CDER
Disqualified
05/08/2008
05/18/2006
12/21/2007
PDF Text
PDF Text
Prev
|
Next
|
1
|
[2]
|
3
|
4
|
5
|
First
|
Last
|
All
1. Under regulations in effect until 1987, investigators who met the standard for disqualification (repeated or deliberate failure to comply with applicable requirements) could potentially avoid disqualification and continue to be eligible to receive investigational products if they could provide FDA with adequate assurances of future compliance with requirements applicable to the use of investigational drugs and biologics. The provisions for adequate assurances are no longer in the regulations.